Cargando…

Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus

AIM: To assess the association between SGLT‐2 inhibitors initiation and genital tract infections (GTIs) among patients with type 2 diabetes. METHODS: A population‐based cohort study using administrative healthcare data from Alberta, Canada, and primary care data from the UK’s Clinical Practice Resea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alkabbani, Wajd, Zongo, Arsène, Minhas‐Sandhu, Jasjeet K., Eurich, Dean T., Shah, Baiju R., Alsabbagh, Mhd. Wasem, Gamble, John‐Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research: Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546240/ https://www.ncbi.nlm.nih.gov/pubmed/35460294 http://dx.doi.org/10.1111/dme.14858

Ejemplares similares

Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study
por: Alkabbani, Wajd, et al.
Publicado: (2021)

The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews
por: Pelletier, Ryan, et al.
Publicado: (2020)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Does the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort study
por: Alsabbagh, Mhd. Wasem, et al.
Publicado: (2017)

Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
por: Pelletier, Ryan, et al.
Publicado: (2021)

Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up
por: Eurich, Dean T, et al.
Publicado: (2017)

Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias – A narrative review
por: Huang, Yichang, et al.
Publicado: (2020)

Pharmacists’ chronic disease management in chronic obstructive pulmonary disease: Effect on health services utilization
por: Makhinova, Tatiana, et al.
Publicado: (2023)

The association between the rate of potentially pharmacist-manageable emergency department visits and community income level and primary care provider availability: A spatial analysis
por: Wasem Alsabbagh, Mhd, et al.
Publicado: (2022)

Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus
por: Unnikrishnan, A. G., et al.
Publicado: (2018)

Effectiveness of RADAR: An Innovative Model to Organize Diabetes Care in First Nations Communities
por: Eurich, Dean T., et al.
Publicado: (2023)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Cohort study of medical cannabis authorization and motor vehicle crash-related healthcare visits in 2014–2017 in Ontario, Canada
por: Lee, Cerina, et al.
Publicado: (2021)

Optimal threshold of adherence to lipid lowering drugs in predicting acute coronary syndrome, stroke, or mortality: A cohort study
por: Zongo, Arsène, et al.
Publicado: (2019)

Change in Trajectories of Adherence to Lipid‐Lowering Drugs Following Non‐Fatal Acute Coronary Syndrome or Stroke
por: Zongo, Arsène, et al.
Publicado: (2019)

Effect of a pharmacy comprehensive chronic diseases care plan on use of lipid-lowering drugs among patients with hypertension
por: Zongo, Arsène, et al.
Publicado: (2021)

Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol
por: Butterly, Elaine, et al.
Publicado: (2022)

Safe opioid prescribing: a prognostic machine learning approach to predicting 30-day risk after an opioid dispensation in Alberta, Canada
por: Sharma, Vishal, et al.
Publicado: (2021)

Concurrent use of opioids and benzodiazepines/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: a case cross-over study
por: Sharma, Vishal, et al.
Publicado: (2020)

The Darkening Cloud of Diabetes: Do trends in cardiovascular risk management provide a silver lining?
por: Eurich, Dean T., et al.
Publicado: (2008)

Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study
por: Scoccimarro, Daniele, et al.
Publicado: (2021)

Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study
por: Lau, Darren, et al.
Publicado: (2013)

Prevalence and determinants of human papillomavirus genital infection in men
por: Franceschi, S, et al.
Publicado: (2002)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
por: Kahkoska, Anna R., et al.
Publicado: (2021)

Characterisation of concurrent use of prescription opioids and benzodiazepine/Z-drugs in Alberta, Canada: a population-based study
por: Sharma, Vishal, et al.
Publicado: (2019)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
por: Sütő, Gábor, et al.
Publicado: (2021)

Epidemiology of genital warts in the British population: implications for HPV vaccination programmes
por: Sonnenberg, Pam, et al.
Publicado: (2019)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Predicting falls-related admissions in older adults in Alberta, Canada: a machine-learning falls prevention tool developed using population administrative health data
por: Sharma, Vishal, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience
por: Shah, Bhupesh R, et al.
Publicado: (2022)

Proportion and risk indicators of nonadherence to antihypertensive therapy: a meta-analysis
por: Lemstra, Mark, et al.
Publicado: (2014)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ei4qufppdeqbesd53gq0klct1m